**Core tip:** We tested the sensitivity of human gastric cancer cells SGC7901/DDP and SGC7901 for cisplatin and compared their mRNA expression profile using a human mRNA microarray, and then performed bioinformatics analysis to depict comprehensively the properties of the differentially expressed mRNAs. Results demonstrated that the dysregulated mRNA were enriched in functions and pathways that may be involved in cisplatin resistance. Exploration of the dysregulated genes could suggest a promising strategy in diagnosis and therapy of gastric cancer with cisplatin resistance.

INTRODUCTION
============

Gastric cancer is the fourth most common cancer and the second leading cause of cancer death globally\[[@B1]\], and more than two thirds of patients when diagnosed with unresectable disease\[[@B2]\]. The 5-year overall survival rate of patients with advanced gastric cancer approximately 25%\[[@B3]\]. Currently, platinum-based chemotherapy regimen is the standout chemotherapy frequently used for advanced gastric cancer\[[@B4],[@B5]\], and median overall survival and progression free survival was significantly longer in cisplatin-containing combination therapy compared to non-cisplatin containing regimens\[[@B6],[@B7]\]. However, cisplatin-based chemotherapeutic agents are often limited in chemotherapy due to drug resistance\[[@B8],[@B9]\].

Cisplatin resistance of gastric cancer is multifactorial, accumulating evidence have suggested that the aberrant expression of proteins which associated with decreased cellular accumulation, increased DNA repair capacity, increased drug inactivation\[[@B10]\] play important role in the acquisition of cisplatin resistance. Previous researches have shown that abnormal expression of copper transporter 1 (CTR1) and MRP2 lead to cisplatin resistance by reducing the concentration of cisplatin in cells\[[@B11]-[@B13]\]. Moreover, the upregulation of excision repair cross complementing 1 (*ERCC1*)\[[@B14]\], X-ray repair cross complementing 1 (*XRCC1*)\[[@B15]\] and breast cancer 1 (*BRCA1*)\[[@B16]\] have shown to be involved in cisplatin resistance by removal of Pt-DNA adducts\[[@B17],[@B18]\]. Other studies have shown that downregulation of the human epidermal growth factor receptor II (ErbB2) can significantly enhanced the apoptosis-inducing effects of cisplatin in gastric cancer\[[@B19],[@B20]\].

The mechanisms of cisplatin resistance are quite complex and have not been fully revealed till now, so investigation of the molecular mechanisms and biomarkers is urgently needed. This study aims to analyze mRNA expression proﬁles in SGC7901/DDP cells to explore more chemotherapeutic molecular targets and to guide appropriate chemotherapy for gastric cancer with cisplatin resistance.

MATERIALS AND METHODS
=====================

Cell lines and culture
----------------------

The human cisplatin-resistant gastric cancer cell line SGC7901/DDP and its parental cells SGC7901 were purchased from KeyGEN Biotechnology Company (Nanjing, Jiangsu, China). Cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, United States) containing 10% fetal calf serum (Gibco, NY, United States) supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were cultured in a humidified atmosphere with 5% CO~2~ at 37 °C. Cisplatin (Sigma, CA, United States) with final concentration of 800 ng/mL was added to the culture media for SGC7901/DDP cells to maintain the cisplatin-resistant phenotype.

MTT method assay for SGC7901/DDP and SGC7901 cells viability
------------------------------------------------------------

SGC7901/DDP and SGC7901 cells were suspended at a density of 1 × 10^5^ cells/mL and planted into 96-well culture plate. After 24 hours, the cells were treated with freshly prepared DDP. The final concentrations were 133.34 μmol /L, 66.67 μmol/L, 6.67 μmol/L, 0.67 μmol/L and 0.067 μmol/L, because the human peak plasma concentration for DDP has been reported as 6.67 μmol/L\[[@B21]\]. Cell viability was examined after 48 h and was determined by adding 20 μL MTT (5 mg/mL) to each well and incubated for a further 4 h. The resulting formazan crystal was dissolved by addition of 150 μL dimethyl sulfoxide (DMSO) (sigma, Germany) each well, and then plates were shaken for 10 minutes. The absorbance at 490 nm was measured by spectrophotometer (ELx 800; BioTek; Winooski, VT, United States). The inhibition of growth (IC50) for DDP was calculated by the cells relative viability. Each experiment was performed in triplicate.

Total RNA extraction and mRNA microarray
----------------------------------------

Cells were harvested when they had grown to 80%-90% confluency and were still in logarithmic phase. Total RNA was extracted from the three matched pairs of SGC7901/DDP and SGC7901 cells using TRIzol reagent (Invitrogen, Carlsbad, CA, United States) according to the manufacturer's instructions. The quality of total RNA was measured by NanoDrop ND-2000 spectrophotometer (Thermo Scientific, Waltham, MA, United States). Total RNA from three paired samples were amplified and transcribed into fluorescent cDNA, and then the fluorescent labeled samples were hybridized to the Agilent LncRNA-mRNA Human Gene Expression Microarray V4.0 (Capital Bio Corp, Beijing, China) which contains 25069 human mRNA according to the manufacturer's recommendations. The microarray was scanned by an Agilent Microarray Scanner. Image processing was conducted using Agilent Feature Extraction software and raw microarray signals normalized using Agilent Gene-Spring software. The normalized mRNA expression profiles data output was received in Excel spreadsheets. The two group of samples data were analyzed by *t*-test to get the *P*-values. FC values representing the differently expressed mRNAs between SGC7901/DDP and their parental cells. Cluster 3.0 software was performed to show differential expression patterns of mRNAs.

Bioinformatics analysis
-----------------------

Bioinformatics analysis were generated using KOBAS software and STRING 9.1 software. KOBAS software was used to analyze Ontology, Disease and pathways of the dysregulated mRNAs. KOBAS associated with 1 ontology database (Gene Ontology), 5 disease databases (OMIM, KEGG DISEASE, PID Reactome, FunDO, GAD, NHGRI) and 7 pathway databases (KEGG PATHWAY, PID Curated, PID BioCarta, BioCyc, eactome, Panther). The entire analysis process includes two steps: first, bring the input gene ID map to the gene in the databases, and then annotate pathways, disease and function of these genes involved in. Second step, compare the first step results with background (usually the entire genome of the gene, or the entire probe on the chip), and unearth statistically significant enrichment pathways, disease or function. Fisher's exact test and χ^2^ test were used as statistical tests and the FDR was performed to correct the *P*-value\[[@B22]\]. Additionally, we used STRING 9.1 software to decipher the protein-protein interaction (PPI) network of the differentially expressed proteins. The PPI network may help in understanding the molecular mechanism of cisplatin resistance. All mRNA microarray data were given by Capital Bio Corp.

Quantitative real-time PCR validation of microarray results
-----------------------------------------------------------

To validate the reliability of microarray analysis, we performed quantitative real-time PCR (qRT-PCR). The reverse transcription production cDNA was synthesized using oligo-dT primers and Superscript II reverse transcriptase. PCR was performed with SYBR^®^ Premix Ex Taq^TM^ (TaKaRa Bio; Japan) by a Light Cycler PCR system (Agilent Technologies, Palo Alto, CA, United States) according to the manufacturer's instructions. After amplification, melting curves were analyzed. Beta-actin snRNA used as endogenous control, each sample was done in triplicate. The relative expression levels of target mRNAs were calculated using the 2^-∆∆Ct^ method (where ∆∆Ct is the difference in threshold cycles for the ∆Ct of SGC7901/DDP sample and SGC7901 sample, and ∆Ct is the difference between the target gene and endogenous control beta-actin). Sequences of primers for qRT-PCR are provided in supporting Table [1](#T1){ref-type="table"}.

###### 

Primer of quantitative real-time polymerase chain reaction

  **ID**   **Primer**   **Sequence (5\'to3\')**     **Base (bp)**   **Tm (**°C**)**   **GC**
  -------- ------------ --------------------------- --------------- ----------------- --------
  HIPK2    Forward      CCCCGTGTACGAAGGTATGG        20              59.90             60%
           Reverse      GGGATGTTCTTGCTCTGGCT        20              60.03             55%
  PDE3B    Forward      TGAGAGTTATGGCTGCCTGT        20              58.72             50%
           Reverse      CTGAGGGGCATTTGTAGCCA        20              60.30             55%
  FGF2     Forward      TCCACCTATAATTGGTCAAAGTGGT   25              59.99             40%
           Reverse      CATCAGTTACCAGCTCCCCC        20              59.82             60%
  TWIST1   Forward      ATTCAAAGAAACAGGGCGTGG       21              59.39             47.6%
           Reverse      CAGAGGTGTGAGGATGGTGC        20              60.39             40%
  ZEB2     Forward      GCCTCTGTAGATGGTCCAGTGA      22              61.21             54.6%
           Reverse      ATCGCGTTCCTCCAGTTTTCT       21              60.00             47.6%
  VEGFC    Forward      CCCGCCTCTCCAAAAAGCTA        20              60.04             55%
           Reverse      CGGGTGTCAGGTAAAAGCCT        20              59.96             55%
  SPHK1    Forward      GCTGCGAAGTTGAGCGAAAA        20              60.04             50%
           Reverse      CGTTCCCTACAGTGGCCTG         19              60.08             63.2%
  BAX      Forward      GCCCTTTTGCTTCAGGGTTT        20              59.24             50%
           Reverse      CATCCTCTGCAGCTCCATGT        20              59.82             55%
  PTEN     Forward      CAGGATACGCGCTCGGC           17              60.73             70.6%
           Reverse      ACAGCGGCTCAACTCTCAAA        20              57.89             50%
  HTRA1    Forward      AGCCAAAGAGCTGAAGGACC        20              59.96             55%
           Reverse      GACATCATTGGCGGAGACCA        20              60.11             55%
  CCL5     Forward      TGCTGCTTTGCCTACATTGC        20              59.76             50%
           Reverse      CTTGTTCAGCCGGGAGTCAT        20              60.04             55%
  TGM2     Forward      CCTCTGTCTCTCCGGGAACC        20              61.32             65%
           Reverse      TGGCAACCAGGGGTCCTAT         19              60.23             57.9%
  TLR4     Forward      CTCGGTCAGACGGTGATAGC        20              59.97             60%
           Reverse      TTTAGGGCCAAGTCTCCACG        20              59.68             55%
  ACTB     Forward      CTCACCATGGATGATGATATCGC     23              59.13             47.8%
           Reverse      AGGAATCCTTCTGACCCATGC       21              59.79             52.4%

GC: Gastric cancer.

Statistical analysis
--------------------

MTT test and qRT-PCR statistical analysis was performed using GraphPad Prism software (v. 5.0a; GraphPad Software, La Jolla, CA, United States). We used one-way analysis of variance (ANOVA) followed by Student's *t*-test to assess the statistical significance of differences between different cell groups. The threshold for statistical significance was *P*-values \< 0.05. Fold changes of mRNAs validated by qRT-PCR in SGC7901/DDP cells compared with SGC7901 cells are shown as mean ± SD.

RESULTS
=======

Sensitivity of SGC7901/DDP and SGC7901 cells to DDP
---------------------------------------------------

To determine the chemotherapy sensitivity of SGC7901/DDP and SGC7901 cell line to cisplatin, varying concentrations of cisplatin were added into the 96-well plates and incubated for 48 h. From these data, half maximal inhibitory concentration (IC50) cisplatin dose was calculated. IC50 cisplatin doses for SGC7901/DDP and SGC7901 (after 48 h in DDP-containing media) were 43.47 ± 0.21 μmol/L and 1.24 ± 0.02 μmol/L, respectively, and the resistance index for SGC7901/DDP cell lines was 35.12, confirming that these cells are refractory to cisplatin. Cell viability was checked by MTT assay (Figure [1](#F1){ref-type="fig"}).

![Cell viability treated with different concentrations of cisplatin for 48 h. MTT assay for SGC7901 cells and SGC7901/DDP cells treated with cisplatin (133.34, 66.67, 6.67, 0.67 and 0.067 μmol/L, respectively).](WJG-23-1189-g001){#F1}

Expression profile of mRNAs in SGC7901/DDP cells
------------------------------------------------

To show mRNA expression profile in cisplatin-resistant SGC7901/DDP cells, we used a stringency cutoff to identify significantly differently mRNAs (*P* \< 0.05, FC ≥ 2) and two-dimensional hierarchical clustering 3.0 to represent expression profiles between samples (Figure [2](#F2){ref-type="fig"}). The results indicated that 1308 mRNAs were significantly differentially expressed in SGC7901/DDP cells compared with SGC7901 cells. Among these transcripts, 578 mRNAs were upregulated, and 730 mRNAs were downregulated.

![mRNA expression levels from microarray. A: The volcano plot image showed the mRNA expression levels of microarray in SGC7901/DDP cells compared with SGC7901 cells. Black dots: equally expressed mRNAs between SGC7901/DDP cells and SGC7901 cells (FC ≤ 2); red dots: mRNAs were over-expressed in SGC7901/DDP cells compared with SGC7901 cells (FC ≥ 2); green dots: mRNAs in SGC7901/DDP cells were down-expressed compared to SGC7901 cells (*P*-values \< 0.05, FC ≥ 2). Fold changes of these mRNAs in SGC7901/DDP cells compared with SGC7901 cells are shown as mean ± SD; B: Two-dimensional hierarchical clustering image of the 1308 dysregulated mRNAs in the SGC7901/DDP cells compared with the SGC7901 cells, each row represents an mRNA, each column represents a sample. 7901-1, 7901-2 and 7901-3 represent the three samples of SGC7901 cells, DDP-1, DDP-2 and DDP-3 represent the three samples of SGC7901/DDP cells. Red: Higher expression levels; green: Lower expression levels.](WJG-23-1189-g002){#F2}

Validation of microarray results by qRT-PCR of 13 mRNAs
-------------------------------------------------------

First, we concentrated on validating the microarray results. From the abnormally expressed (*P* \< 0.05) mRNAs obtained from the microarray analyses, we selected 8 upregulated mRNAs (*HIPK2, PDE3B, FGF2, TWIST1, ZEB2, VEGFC, SPHK1, BAX*) and 5 downregulated (*PTEN, HTRA1, CCL5, TGM2, TLR4*) mRNAs for qRT-PCR validation. The relative fold-changes (SGC7901/DDP *vs* SGC7901) detected by qRT-PCR were consistent with the microarray results (Figure [3](#F3){ref-type="fig"}), indicating the dependability of our microarray platform.

![Quantitative real-time polymerase chain reaction validation of the microarray results of the 13 mRNAs. Relative fold changes in expression between SGC7901/DDP cells and SGC7901 cells were in agreement with microarray.](WJG-23-1189-g003){#F3}

Statistical analysis
--------------------

To depict comprehensively the properties of the differentially expressed mRNA in SGC7901/DDP cells, GO annotation and enrichment analysis was performed to evaluate which cellular components, molecular functions and biological processes may be are affected by this dysregulation. The GO enrichment analysis showed that the differentially expressed genes were involved in a variety of functions, including locomotion, chemotaxis, cell adhesion, regulation of cell migration, extracellular matrix disassembly, response to xenobiotic chemotaxis, localization of cell adhesion and blood vessel morphogenesis (Figure [4A](#F4){ref-type="fig"}).

![Bioinformatic analysis of differentially expressed mRNAs. Gene ontology analysis of mRNAs dysregulated in SGC7901/DDP cells compared with SGC7901 cells. A: Top 30 molecular functions of the dysregulated mRNAs may associated with. Gene ontology analysis include biological processes, cellular components and molecular function; B: Gene ontology enriched diseases. Top 30 diseases annotations of dysregulated mRNAs may involve in. The disease enrich system include 5 disease databases: OMIM, KEGG disease, FunDO, GAD and NHGRI GWAS Catalog.](WJG-23-1189-g004){#F4}

Additionally, 59 human diseases were significant enriched (*P* \< 0.05) in five human disease databases (KEGG DISEASE, FunDO, GAD, NHGRI GWAS Catalog and OMIM) (Figure [4B](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Furthermore, it is worth noting that in KEGG disease database, gastric cancer is the most highly enriched disease, and the input genes include *DCC, CD44, CDH1, VEGFC, EGF, TGFA*.

###### 

Different expressed mRNAs enriched by KOBAS

  **Term**                                                  **Database**         ***P* value**   **Input gene symbols**
  --------------------------------------------------------- -------------------- --------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gastric cancer                                            KEGG DISEASE         0.0016          *DCC, CD44, CDH1, VEGFC, EGF, TGFA*
  Skin diseases                                             KEGG DISEASE         0.0078          *DSP, TGM1, CCL5, IL31RA, SPINK5, HLA, FERMT1, KRT14, CTSC, COL17A1, LAMA3, REEP1, RIN2, ALOXE3, ABCC6, WNT10A, FBLN5*
  Skin and soft tissue diseases                             KEGG DISEASE         0.0078          *DSP, TGM1, CCL5, IL31RA, SPINK5, HLA, FERMT1, KRT14, CTSC, COL17A1, LAMA3, REEP1, RIN2, ALOXE3, ABCC6, WNT10A, FBLN5*
  Macular degeneration                                      KEGG DISEASE         0.0140          *C3, FBLN5, CFH, TLR4*
  Cancers of the digestive system                           KEGG DISEASE         0.0439          *DCC, CD44, CDH1, VEGFC, EGF, TGFA*
  Familial thoracic aortic aneurysm and dissection (TAAD)   KEGG DISEASE         0.0459          *MYLK, TGFBR1*
  Hypomagnesemia                                            KEGG DISEASE         0.0459          *TRPM6, EGF*
  Multiple epiphyseal dysplasia (MED)                       KEGG DISEASE         0.0459          *COL9A3, MATN3*
  Transient neonatal diabetes mellitus (TNDM)               KEGG DISEASE         0.0459          *PLAGL1, ZFP57*
  Non-syndromic autosomal dominant mental retardation       KEGG DISEASE         0.0461          *EPB41L1, DOCK8, PACS1, SMARCA4*
  Cardiac hypertrophy                                       NHGRI GWAS Catalog   0.0028          *PLXNA2, GRIK2, COL17A1, JAG1, SNAP25, BTBD3, SLX4IP*
  Response to fenofibrate (adiponectin levels)              NHGRI GWAS Catalog   0.0046          *OAS2, PMEPA1, SHANK2, SCUBE1, SLC30A4, PCK1*
  Complement C3 and C4 levels                               NHGRI GWAS Catalog   0.0094          *HLA, CFHR3, CFH, C3*
  Neutrophil count                                          NHGRI GWAS Catalog   0.0119          *PLCB4, TGFA, FGGY, PDGFD, PSD3*
  Nephropathy(idiopathic membranous)                        NHGRI GWAS Catalog   0.0137          *HLA, ITGB6, PLA2R1*
  Sleep duration                                            NHGRI GWAS Catalog   0.0195          *PLLP, TMC5, ADAMTS14*
  Airflow obstruction                                       NHGRI GWAS Catalog   0.0259          *HYKK, LEF1, SERPINB8, GPR126, MAP3K13, PTPRD*
  Cystic fibrosis severity                                  NHGRI GWAS Catalog   0.0265          *HLA, EHF, AHRR*
  Metabolite levels (5-HIAA/ MHPG Ratio)                    NHGRI GWAS Catalog   0.0265          *PIEZO2, ROBO2, ADAM12*
  Bronchopulmonary dysplasia                                NHGRI GWAS Catalog   0.0296          *PLXDC2, ZNF770, SPOCK1, TRPS1, RASGRF1, HIVEP3*
  Major depressive disorder                                 NHGRI GWAS Catalog   0.0346          *PCLO, SLC6A15, ENOX1, SYPL2, IGFBP1, IGFBP3, C12orf5, ATXN1, PIEZO2, TRPS1, RASGEF1B, FGF12, KCNH5*
  IgA nephropathy                                           NHGRI GWAS Catalog   0.0346          *HLA, ACOXL, TNFSF13*
  Pulmonary function decline                                NHGRI GWAS Catalog   0.0368          *MUSK, CSMD1, RORA, FLRT2*
  Palmitic acid (16:0) plasma levels                        NHGRI GWAS Catalog   0.0368          *SCD, CNN3, GRIK2, PTPRD*
  Male-pattern baldness                                     NHGRI GWAS Catalog   0.0439          *AUTS2, EDA2R, AR*
  Response to citalopram treatment                          NHGRI GWAS Catalog   0.0439          *LAMA1, RORA, EGFLAM*
  Hyperlipidemia                                            FunDO                0.0050          *IRS1, CCL5, C3, PAPPA, TXNIP, APOC1, F3, SCD*
  Thrombocytopenia                                          FunDO                0.0068          *GATA1, CCL5, ITGB3, IL11, CXCL8, MPL*
  Fibromyalgia                                              FunDO                0.0126          *MAOB, CXCL8, BDNF, IGFBP3*
  Cirrhosis                                                 FunDO                0.0209          *RBP4, KRT18, IGFBP3, KRT8, EGF, F3, FGF2IGFBP1*
  Hepatitis C                                               FunDO                0.0321          *CD274, CCL5, RBP4, MKI67, CXCL8, KRT18, TLR4, KRT8, FGF2*
  Thalassemia                                               FunDO                0.0345          *LCN2, CXCL8, ANK2, KIR3DL1, MUC1*
  Gingival overgrowth                                       FunDO                0.0417          *EDN1, IL15, FGF7*
  Pulmonary fibrosis                                        FunDO                0.0474          *CSF1, BDNF, MMP7, EDN1, CCL5, ERBB3*
  Ovary cancer                                              FunDO                0.0477          *LCN2, IL15, CXCL8, FGF7, CASP1*
  Esophageal tumor                                          FunDO                0.0477          *CD274, TSPAN8, FRAT1, PDCD1LG2, FGF7*
  Hyperlipidemia                                            GAD                  0.0093          *CCL5, HLA, CXCL8, CD22, TNFRSF1B, CD19*
  Thrombocytopenia                                          GAD                  0.0114          *CSMD1, DOCK4, GALNTL6, SOBP, PLXDC2, SESN3, ADAMTS5, EHF, TMC5, LPL, CD109, FAM117B, PDE1C, TAGLN, PTN, FGD4, DYNC2H1, GNG4, MUSK, FBLN5, CCDC54, TTC9, PMEPA1, TLR4, ANK3, EDA2R, APOC1, BMP2, TOX3, NRG1, ITPK1, PTPRD, KLF6, PAM, PTPRU, LEPR, IKZF2, LHX5, MCTP2, ANKRD50, SEMA6D, PLXNA2, DPYD, GRIK2, SRGAP3, ACOXL, TDRKH, FAM135B, VEGFC, CHST2*
  Fibromyalgia                                              GAD                  0.0136          *GLI3, CELF2, VWA3B, PLXDC2, EDNRA, EDN1, JUN, DOCK8, DCLK2, BTBD3, DCN, CD74, EGFLAM, TLL1, TLR4, BMP2, PTPRD, ANK2, PTPRU, JADE2, IGF2BP2, PAPPA, DOCK2, KLK4, FAM49A, RGS3, AATK, FN1, IGSF10, NCOA7, SCIN, TNS1, FAM135B, MUC16, ADAM19, ATXN1, MTUS2, NXNL2, KCNQ3, ANPEP, CDH2*
  Cirrhosis                                                 GAD                  0.0204          *IRS1, CCL5, ITGB3, NPR1, NPR3, APOC1, LPL*
  Hepatitis C                                               GAD                  0.0258          *DPYD, CELF4, CELF2, FAM117B, TDRKH, LPCAT4, FBLN5, SOBP, PMEPA1, CSMD1, STOX1, CACNB2, CADM1, VEGFC, SLC7A11, LPL, CD109, MCTP2, SLC24A2, PTPRD, ITPK1*
  Thalassemia                                               GAD                  0.0362          *MCTP2, PSD3, CCDC54, ROBO2, ELOVL6*
  Gingival overgrowth                                       GAD                  0.0419          *PLXNA2, ATXN1, IGF2BP2, ABCA13, FN1*
  Pulmonary fibrosis                                        GAD                  0.0420          *CREG2, GALNTL6, LINC01550, KIF16B, SH3BGR, TRPS1, PDE1C, NCKAP5, TNFRSF21, RYR3, MAGEC2, EDIL3, CXCL16, MCF2, DTD1, GPC5, KLF6, IKZF2, KCNH5, AJAP1, BTBD3, PHACTR2, ITPK1, IGSF10, SRGAP3, C12orf75, ABI3BP, FOS, SCUBE1*
  Ovary cancer                                              GAD                  0.0426          *CELF4, TRPS1, TWIST1, PQLC2L, MAL2, PSD3, RCAN2, SUPT3H, TGFA, TMEM131L, HIVEP3, CSMD1, ROBO2, CCDC54, PRNP, APOC1, HRK, GPC5, AR, FN1, ABCA13, F2RL2, KLF6, IGF2BP2, LEPREL1, GNG4, SNAP25, MCTP2, FAM49A, ANKRD50, CACNA2D1, PLXNA2, ELOVL6, RUNX2, SCN8A, ATXN1, ID2, SLC24A2, CMTM7, LINGO2*
  Esophageal tumor                                          GAD                  0.048           *CACNA2D1, SLC46A3, CHST2, PKDCC, PPID, CDH2*

To determine which pathway might be involved in drug resistance formation, KEGG pathway analysis was used to authenticate pathways and understand biological functions of significantly differentially expressed genes. The result indicated that the differentially expressed mRNAs were enriched for 233 pathways, including the *Rap1* signaling pathway, *PI3K-Akt* signaling pathway, *ECM*-receptor interaction, *TNF* signaling pathway, and pathways in cancer, among others (Figure [5](#F5){ref-type="fig"}, Table [3](#T3){ref-type="table"}). Cluster 3.0 software were performed the heat-map.This finding identified many candidate pathways and input genes that may play an important role in resistance mechanism.

###### 

Cisplatin resistance pathway and input gene (*P* \< 0.05, FC ≥ 2.0)

  **Pathway**                   **Input gene**   **Fold change**   **Regulation**   **Genomic coordinates**     **Cyto band**
  ----------------------------- ---------------- ----------------- ---------------- --------------------------- ---------------
  PI3K-Akt signaling pathway    *LAMA1*          2.60826           Up               Chr18:6958512-6956742       hs\|18p11.31
                                *LAMA1*          2.75269           Up               Chr18:6942035-6941976       hs\|18p11.31
                                *GNG4*           2.09356           Up               Chr1:235714443-235714384    hs\|1q42.3
                                *ITGB3*          2.96629           Up               Chr17:45389027-45389086     hs\|17q21.32
                                *ITGB6*          7.72783           Up               Chr2:160964233-160958330    hs\|2q24.2
                                *VEGFC*          2.92538           Up               Chr4:177604882-177604823    hs\|4q34.3
                                *PDGFD*          2.42861           Up               Chr11:103778445-103778386   hs\|11q22.3
                                *IRS1*           2.00967           Up               Chr2:227596677-227596618    hs\|2q36.3
                                *GNGT1*          2.04779           Up               Chr7:93536149-93540155      hs\|7q21.3
                                *CSF1*           2.25620           Up               Chr1:110466137-110466196    hs\|1p13.3
                                *EGF*            4.76437           Up               Chr4:110932689-110932748    hs\|4q25
                                *FGF2*           3.02437           Up               Chr4:123819331-123819390    hs\|4q28.1
                                *FGF2*           2.99240           Up               Chr4:123819317-123819376    hs\|4q28.1
                                *FN1*            2.31254           Up               Chr2:216288895-216288217    hs\|2q35
                                *COL4A6*         2.08497           Up               Chrx:107399109-107399050    hs\|Xq22.3
                                *FGF12*          10.99211          Up               Chr3:191860574-191860515    hs\|3q28
                                *GNG11*          2.01984           Up               Chr7:93555764-93555823      hs\|7q21.3
                                *FGF7*           2.19252           Up               Chr15:49776810-49776869     hs\|15q21.2
                                *LAMA3*          2.56116           Down             Chr18:21534735-21534794     hs\|18q11.2
                                *IFNA21*         2.30808           Down             Chr9:21166331-21166272      hs\|9p21.3
                                *CREB3L3*        2.40183           Down             Chr19:4172219-4172278       hs\|19p13.3
                                *TLR4*           2.13271           Down             Chr9:120476856-120476915    hs\|9q33.1
                                *COL6A2*         2.89458           Down             Chr21:47546086-47546145     hs\|21q22.3
                                *CD19*           2.09302           Down             Chr16:28950600-28950659     hs\|16p11.2
                                *LPAR5*          3.83177           Down             Chr12:6728794-6728735       hs\|12p13.31
                                *COL4A4*         2.11177           Down             Chr2:227867523-227867464    hs\|2q36.3
                                *PCK1*           4.49558           Down             Chr20:56141030-56141089     hs\|20q13.31
                                *VTN*            3.82587           Down             Chr17:26694806-26694747     hs\|17q11.2
                                *GNGT2*          16.48365          Down             Chr17:47284034-47283975     hs\|17q21.32
                                *IL2RG*          2.87954           Down             Chrx:70328539-70328480      hs\|Xq13.1
                                *COL5A3*         7.53410           Down             Chr19:10070602-10070543     hs\|19p13.2
                                *FGF13*          17.08866          Down             Chrx:137713947-137713888    hs\|Xq26.3
  MAPK signaling pathway        *FLNC*           4.57879           Down             Chr7:128498538-128498597    hs\|7q32.1
                                *FLNC*           4.81302           Down             Chr7:128498476-128498535    hs\|7q32.1
                                *CACNB2*         7.83293           Down             Chr10:18787305-18787364     hs\|10p12.31
                                *RASGRF1*        4.87152           Down             Chr15:79254554-79254495     hs\|15q25.1
                                *FOS*            2.17501           Down             Chr14:75748214-75748273     hs\|14q24.3
                                *JUN*            2.04000           Down             Chr1:59246570-59246511      hs\|1p32.1
                                *RASGRP2*        3.10358           Down             Chr11:64508971-64508912     hs\|11q13.1
                                *FGF13*          17.08866          Down             Chrx:137713947-137713888    hs\|Xq26.3
                                *TGFBR1*         2.93035           Up               Chr9:101916322-101916381    hs\|9q22.33
                                *TGFBR1*         4.76437           Up               Chr4:110932689-110932748    hs\|4q25
                                *EGF*            4.76437           Up               Chr4:110932689-110932748    hs\|4q25
                                *FGF12*          10.99211          Up               Chr3:191860574-191860515    hs\|3q28
                                *MAP3K13*        2.25019           Up               Chr3:185161379-185165590    hs\|3q27.2
                                *FGF2*           3.02437           Up               Chr4:123819331-123819390    hs\|4q28.1
                                *FGF2*           2.99240           Up               Chr4:123819317-123819376    hs\|4q28.1
                                *MAP2K7*         2.08267           Up               Chr19:7979302-7979361       hs\|19p13.2
                                *FGF7*           2.19252           Up               Chr15:49776810-49776869     hs\|15q21.2
                                *CACNG4*         8.83585           Up               Chr17:65028139-65028198     hs\|17q24.2
                                *CACNG4*         2.94145           Up               Chr17:65029115-65029174     hs\|17q24.2
                                *CACNB4*         2.14311           Up               Chr2:152694239-152694180    hs\|2q23.3
                                *GADD45A*        2.56659           Up               Chr1:68153371-68153430      hs\|1p31.3
                                *BDNF*           2.32411           Up               Chr11:27679959-27679900     hs\|11p14.1
                                *BDNF*           2.30323           Up               Chr11:27677072-27677013     hs\|11p14.1
                                *CACNA2D1*       2.09452           Up               Chr7:81579504-81579445      hs\|7q21.11
  Notch signaling pathway       *MAML2*          2.03379           Up               Chr11:95712434-95712375     hs\|11q21
                                *JAG1*           3.20086           Up               Chr20:10619120-10619061     hs\|20p12.2
                                *MAML3*          2.57919           Up               Chr4:140810806-140810747    hs\|4q31.1
                                *DTX4*           9.99859           Down             Chr11:58975615-58975674     hs\|11q12.1
  ErbB signaling pathway        *EGF*            4.76437           Up               Chr4:110932689-110932748    hs\|4q25
                                *NRG1*           2.77996           Up               Chr8:32474390-32585512      hs\|8p12
                                *MAP2K7*         2.08267           Up               Chr19:7979302-7979361       hs\|19p13.2
                                *JUN*            2.04000           Down             Chr1:59246570-59246511      hs\|1p32.1
                                *ERBB3*          5.29571           Down             Chr12:56482380-56482439     hs\|12q13.2
                                *ERBB3*          8.12050           Down             Chr12:56496160-56496219     hs\|12q13.2
                                *TGFA*           2.37427           Down             Chr2:70675378-70675319      hs\|2p13.3
  Jak-STAT signaling pathway    *IL11*           4.21849           Up               Chr19:55875847-55875788     hs\|19q13.42
                                *IL15*           2.92970           Up               Chr4:142654431-142654490    hs\|4q31.21
                                *SOCS2*          2.00180           Up               Chr12:93969799-93969858     hs\|12q22
                                *SPRY1*          5.95682           Up               Chr4:124324494-124324553    hs\|4q28.1
                                *LEPR*           2.90187           Up               Chr1:66102129-66102188      hs\|1p31.3
                                *IL2RG*          2.87954           Down             Chrx:70328539-70328480      hs\|Xq13.1
                                *MPL*            3.41581           Down             Chr1:43819826-43819885      hs\|1p34.2
  NF-kappaB signaling pathway   *CXCL2*          2.03846           Up               Chr4:74963044-74962985      hs\|4q13.3
                                *CXCL8*          9.97781           Up               Chr4:74609265-74609324      hs\|4q13.3
                                *TLR4*           2.13271           Down             Chr9:120476856-120476915    hs\|9q33.1
  HIF-1 signaling pathway       *EDN1*           2.39081           Up               Chr6:12296672-12296731      hs\|6p24.1
                                *EDN1*           2.46437           Up               Chr6:12296218-12296277      hs\|6p24.1
                                *EGF*            4.76437           Up               Chr4:110932689-110932748    hs\|4q25
                                *TLR4*           2.13271           Down             Chr9:120476856-120476915    hs\|9q33.1
  MicroRNAs in cancer           *IRS1*           2.00967           Up               Chr2:227596677-227596618    hs\|2q36.3
                                *ZEB2*           3.32563           Up               Chr2:145146320-145146261    hs\|2q22.3
                                *ZEB2*           2.70558           Up               Chr2:145182422-145182363    hs\|2q22.3
                                *CD44*           2.02409           Up               Chr11:35253812-35253871     hs\|11p13
                                *RECK*           2.25018           Up               Chr9:36124319-36124378      hs\|9p13.3
                                *ITGB3*          2.96629           Up               Chr17:45389027-45389086     hs\|17q21.32
                                *SERPINB5*       2.61864           Up               Chr18:61172218-61172277     hs\|18q21.33
                                *GLS*            2.36144           Up               Chr2:191829716-191829775    hs\|2q32.2
                                *GLS*            2.07371           Up               Chr2:191827822-191827881    hs\|2q32.2
                                *ERBB3*          5.29571           Down             Chr12:56482380-56482439     hs\|12q13.2
                                *ERBB3*          8.12050           Down             Chr12:56496160-56496219     hs\|12q13.2

![Heat-map of gene ontology enriched cisplatin resistance pathways and input mRNAs which significantly altered in SGC7901/DDP cells compared with SGC7901 cells. A: PI3K-Akt signaling pathway and input genes; B: MAPK signaling pathway and input genes; C: Notch signaling pathway and input genes; D: ErbB signaling pathway and input genes; E: Jak-STAT signaling pathway and input genes; F: NF-kappa B signaling pathway and input genes; G: HIF-1 signaling pathway and input genes; H: MicroRNAs in cancer and input genes. Each row represents an mRNA, and each column represents a sample. The intensity of the color indicates the relative levels of mRNAs. Red: Higher expression levels; green: Lower expression levels. The name of the input mRNAs which significantly altered (*P* \< 0.05, FC ≥ 2) is present at the right of the figure.](WJG-23-1189-g005){#F5}

Interaction network analysis
----------------------------

The STRING 9.1 software (Search Tool for the Retrieval of Interacting Genes) was used to perceive functional relations and generate networks of differential expression of proteins (Figure [6](#F6){ref-type="fig"}). For all of the 1002 differentially expressed proteins, we extracted a network containing 443 upregulated and 559 downregulated proteins which functionally associated with each other. We found that interacting proteins which participate in angiogenesis, toll-like receptor signaling pathway and cell adhesion had a high level of co-expression.

![Interaction network analyses of differentially express proteins. In the network, nodes represents proteins, lines as functional associations between the abnormal expressed proteins and the thickness of the lines indicates the level of confidence in association reported.](WJG-23-1189-g006){#F6}

DISCUSSION
==========

Cisplatin is widely used against a variety of solid neoplasms, including testicular, ovarian, colorectal, bladder, head and neck cancers and gastric cancer\[[@B23]\]. However, the repeated clinical expose to cisplatin often results in the tumor cells evading the apoptosis program initiated by cisplatin. Therefore, there is a need to explore the molecular mechanisms of cisplatin resistance, in order to overcome drug resistance in tumor therapy. Recently, several studies have indicated that many proteins are involved in the recognition of Pt-DNA adducts and cisplatin-induced apoptosis program\[[@B24],[@B25]\]. In this study, we used microarray, GO, KEGG pathway and protein-protein interaction (PPI) analysis to explore the roles of differentially expressed mRNAs in cisplatin resistance and to support other studies.

Many genes which shown differentially expression in the microarray analysis have been demonstrated to be associated with cisplatin resistance in human cancer (Table [4](#T4){ref-type="table"}), such as *PDE3B*, which was substantially upregulated (*P* value = 0.00029, Fold Chang (FC) = 10.45) in SGC7901/DDP cells. Treatment with a combination of a *PDE3B* inhibitor and DDP can significantly increase the number of apoptotic and cell growth-suppressive cancer cells in cisplatin resistant squamous cell carcinoma (SCC) and Hela cells\[[@B26]\]. Research shows that *VEGFC*, which is upregulated in our data (*P* value = 0.00013 FC = 2.93), enhanced cell invasion and cisplatin resistance in gastric cancer\[[@B27]\]. In non-small cell lung cancer, loss of *IGFBP-3* expression may activate the *PI3K/AKT* pathway and induce resistance to cisplatin\[[@B28]\]. In support of this association, our results showed that this mRNA is downregulated (*P* = 0.00007, FC = 2.93) in SGC7901/DDP cells.

###### 

Dysregulated mRNAs (*P* \< 0.05, FC ≥ 2.0) associated with cisplatin resistance

  **Gene symbol**   ***P* value**   **FC (abs)**   **Regulation**   **Genename**                                                  **Ref**.
  ----------------- --------------- -------------- ---------------- ------------------------------------------------------------- --------------------------------
  *FGF7*            0.00035         2.19252        Up               Fibroblast growth factor 7                                    PMID: 22990650
  *HIPK2*           2.63E-06        4.06213        Up               Homeodomain interacting protein kinase 2                      PMID: 24846322
  *EDN1*            9.94E-05        2.46437        Up               Endothelin 1                                                  PMID: 21220476
  *CBS*             0.00108         2.29340        Up               Cystathionine-beta-synthase                                   PMID: 24236104
  *PDE3B*           0.00029         10.44998       Up               Phosphodiesterase 3B, cgmp-inhibited                          PMID: 24133626
  *E2F5*            0.00041         2.42888        Up               E2F transcription factor 5, p130-binding                      PMID: 22193543
  *PIN1*            0.00104         2.13293        Up               Peptidylprolyl cis/trans isomerase, NIMA-interacting 1        PMID: 26820938
  *EGF*             0.00346         4.76437        Up               Epidermal growth factor                                       PMID: 27086487
  *CSF1*            0.00025         2.25620        Up               Colony stimulating factor 1 (macrophage)                      PMID: 22005523
  *PCNA*            0.00103         2.17028        Up               Proliferating cell nuclear antigen                            PMID: 24474685
  *HIPK2*           2.63E-06        4.06213        Up               Homeodomain interacting protein kinase 2                      PMID: 24846322
  *ENTPD6*          0.00011         2.43726        Up               Ectonucleoside triphosphate diphosphohydrolase 6 (putative)   PMID: 21519793
  *AKR1C1*          0.00097         2.29646        Up               Aldo-keto reductase family 1, member C1                       PMID: 23165153, PMID: 17266043
  *ASNS*            0.00172         2.19491        Up               Asparagine synthetase (glutamine-hydrolyzing)                 PMID: 23956056, PMID: 17409444
  *BDNF*            0.00062         2.32411        Up               Brain-derived neurotrophic factor                             PMID: 22276165, PMID: 17044982
  *CABYR*           0.01089         2.55664        Up               Calcium binding tyrosine-(Y)-phosphorylation regulated        PMID: 24362251
  *FGF2*            2.15E-06        2.99240        Up               Fibroblast growth factor 2 (basic)                            PMID: 12894531
  *SLC7A11*         1.95E-05        2.93256        Up               Solute carrier family 7 member 11                             PMID: 24516043
  *TUBB3*           0.00046         2.00213        Up               Tubulin, beta 3 class III                                     PMID: 25107571
  *TWIST1*          0.00180         2.96340        Up               Twist family bhlh transcription factor 1                      PMID: 22673193, PMID: 22245869
  *JAG1*            9.41E-05        3.20086        Up               Jagged 1                                                      PMID: 24659709
  *ANXA11*          0.00031         2.36619        Down             Annexin A11                                                   PMID: 19484149, PMID: 17982121
  *CCL5*            2.67E-05        5.05630        Down             Chemokine (C-C motif) ligand 5                                PMID: 26983899
  *FGF13*           0.00044         17.08866       Down             Fibroblast growth factor 13                                   PMID: 24113164
  *IGFBP3*          7.48E-05        2.92508        Down             Insulin-like growth factor binding protein 3                  PMID: 20023704
  *KLK6*            0.00066         2.24596        Down             Kallikrein-related peptidase 6                                PMID: 23307575
  *SLC7A8*          4.50E-05        5.36735        Down             Solute carrier family 7 member 8                              PMID: 23462296
  *TGM2*            2.88E-05        6.24520        Down             Transglutaminase 2                                            PMID: 21424127, PMID: 24828664
  *TLR4*            0.00114         2.13271        Down             Toll-like receptor 4                                          PMID: 21616060, PMID: 22583829
  *XAF1*            0.02405         3.20613        Down             XIAP associated factor 1                                      PMID: 25824780, PMID: 25240826
  *TCEA2*           0.00061         3.65969        Down             Transcription elongation factor A (SII), 2                    PMID: 16142353

GO enrichment analysis exhibits many functions which the differently expressed mRNAs are involved in, including locomotion, chemotaxis, cell adhesion, regulation of cell migration, extracellular matrix disassembly, response to xenobiotic chemotaxis, localization of cell adhesion and blood vessel morphogenesis. Functional annotation showed that the differently expressed mRNAs mainly regulate cellular biological behaviors in the progress of regulation of transcription. How the underlying targets of each GO term are implicated in the cisplatin resistance needs further investigation in the future.

Our KEGG pathway analysis showed that the differently expressed mRNAs are enriched in pathways of *ECM*-receptor interaction, *PI3K-Akt, Rap1, MAPK, Notch1, ErbB, ABC* transporters, *Jak-STAT, NF-*κ*B, HIF-1* and *TGF-*β. All of those pathways have been confirmed to be involved in cisplatin resistance in different experiments described previously. For example, the inhibition of *PI3K-Ak*t signaling pathway may increase the sensitivity of gastric cancer cells to cisplatin chemotherapy\[[@B29]\]. Another study found that Janus kinase 2 (*JAK2*) signal transducer and activator of transcription 3 (*STAT3*) signaling pathways were activated by overexpressed *AKT* in cisplatin resistant human gastric cancer cells\[[@B30]\]. A study revealed that the canonical *NF-*κ*B* signaling pathway was involved in APRIL-mediated cisplatin resistance in gastric cancer\[[@B31]\]. Our data are consistent with these previous studies, and these pathways and input genes deserve our attention in gastric cancer cisplatin resistance.

Although protein expression is generally stable when organs mature, under various pathological and physiological conditions, gene expression may change and ultimately result in aberrant protein levels. Therefore, research on proteomics is helpful to illustrate some biological mechanisms, including cisplatin resistance. Protein-protein interaction network analysis might uncover previously unknown molecular mechanisms of cisplatin resistance. Hub proteins of subnetworks which interact with many partners might associate with drug resistance. For example, studies have shown that dysregulation of the genes *PDE3B, TLR4*, and *HIPK2* is associated with cisplatin resistance in human SCC cells, ovarian granulosa tumor cells and bladder cancer cells, respectively\[[@B26],[@B32],[@B33]\]. Moreover, hub proteins and their partners may have similar biological functions. Since downregulation of EGF has been shown to substantially overcome resistance to cisplatin in ovarian cancer\[[@B34]\], we predict that the proteins EDN1 and DCN, whose hub protein is EGF, may contribute to cisplatin resistance in a similar fashion. We also found that ZEB2, which over-expressed in SGC7901/DDP compared with SGC7901 has a similar expression profile to TWIST1, suggesting that ZEB2 may play an important role in cisplatin resistance by regulating the expression of TWIST1. Nevertheless, more evidence and research is needed.

In conclusion, our study identified mRNAs differentially expressed between gastric cancer cell lines SGC7901/DDP and SGC7901. These results provide a global view of the function of the differentially expressed mRNAs. Several molecular and pathway abnormalities detected in our study have previously been reported to be associated with drug resistance in gastric cancer. The dysregulated mRNAs identified participate in cisplatin resistance through diverse mechanisms, and further investigation is required to confirm the role in drug resistance of these transcripts, pathways and the interaction networks of the proteins they code for.

COMMENTS
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Background
----------

Cisplatin-contained chemotherapy is one of the most frequently used for advanced gastric cancer; however, this chemotherapeutic agent is often limited due to drug resistance and result unsatisfactory prognosis. Research increasingly suggests that abnormal expression of biological pathway and proteins associated with cisplatin resistance. This demonstrated that more bioinformatics study is needed to predict targets for gastric cancer with cisplatin.

Research frontiers
------------------

Bioinformatics analysis demonstrated that some mRNAs which related to the biological behavior abnormal expression in SGC7901/DDP cells. These mRNAs have already been shown to play important roles in the process of cisplatin resistance of various cancers, including gastric cancer.

Innovations and breakthroughs
-----------------------------

The authors performed bioinformatics analysis of mRNA expression profile in SGC7901/DDP cells compared with SGC7901 cells, and found that many mRNAs and pathways in SGC7901/DDP cells expressed abnormally, these may participate in and predict cisplatin resistance in gastric cancer.

Applications
------------

These results suggest that targeting the differently expression mRNA may provide more selective approaches to reverse cisplatin resistance of therapeutic targets.

Terminology
-----------

The definition of cisplatin resistance: in the clinic, if a patient who have disease recurrence within the first months after the recent cisplatin dose, the patient is considered cisplatin resistance; in cells, generally, resistance index \> 20 exhibited high resistance, resistance index 5-15 is moderate resistance, resistance index \< 5 represent low or no resistance. Correct *P*: Using Benjamini Hochberg FDR method for correction of p values. Fold change (FC): gene expression in SGC7901 / DDP cells compared with SGC7901 cells.
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The paper is a good study on mRNAs expression profile in SGC7901/DDP cells. The investigators shown that many mRNAs was abnormal expressed in SGC7901/DDP cells and these mRNAs enriched in many biological process which have already been shown to play important roles in the process of cisplatin resistance in human cancer.
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